Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC) Market Outlook

Thelansis’s “Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Advanced or Metastatic Non-Small-Cell Lung Cancer treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC) Overview

Lung cancer remains the predominant cause of cancer-related mortality globally among both males and females. The majority of lung cancer cases are classified as non-small cell lung cancer (NSCLC), accounting for approximately 85% of cases. The most prevalent histological subtypes within NSCLC include adenocarcinoma (AC), squamous cell carcinoma (SCC), and large cell neuroendocrine carcinoma (LCNEC). Advanced NSCLC, also referred to as metastatic NSCLC, is characterized by the spread of the cancer from the lungs to other parts of the body, rendering it incurable. In the United States, NSCLC represents the most common form of lung cancer and frequently metastasizes to the bones, brain, liver, skin, lymph nodes, or adrenal glands. However, it can disseminate to any region of the body. Molecular subtyping has become increasingly critical in managing advanced and metastatic NSCLC (stage IV), as genotype-driven therapies, commonly known as targeted therapies, have become the standard of care for a significant subset of patients. These therapeutic advancements have led to unprecedented improvements in patient outcomes. Historically, the estimated median overall survival for patients with stage IV NSCLC was between 6 and 10 months. Advanced NSCLC can be categorized into two forms: locally advanced and metastatic. Locally advanced NSCLC, also referred to as stage III NSCLC, occurs when cancer has spread to lymph nodes further away from the chest but has not metastasized to distant organs. This stage may involve larger tumors compared to stage II NSCLC. Metastatic NSCLC, or stage IV NSCLC, is defined by the spread of cancer to distant organs, such as the contralateral lung, brain, or liver. Current standard practice in the treatment of metastatic NSCLC includes the use of tyrosine kinase inhibitors (TKIs) targeting anaplastic lymphoma kinase (ALK), particularly in ALK-positive patients confirmed through the standard fluorescence in situ hybridization (FISH) technique, or in ROS1-positive patients. Alectinib has emerged as the preferred first-line treatment due to its superior progression-free survival (PFS) compared to crizotinib in direct comparisons.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2023-2033

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: